Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy

Condition studied

Multiple System Atrophy

Investigational medicinal product(s)

Eligibility

Primary endpoint

Assessment of long term safety and tolerability based on incidence and severity of AEs and SAEs, changes in laboratory and vital sign parameters including orthostatic measures, exposure to ATH434, treatment discontinuations due to adverse events, and deaths.